Theseus Pharmaceuticals, which aimed to overcome the resistance that cancers develop to drugs, is laying off most of its staff and exploring options that could lead to deals that eke out some value ...
It’s been a wild November for Theseus Pharmaceuticals. Just a couple of weeks ago, the biotech laid off almost three-quarters of its staff. Days later, the company received offers from two sets of ...
-- Company prioritizing THE-349, a potentially best-in-class fourth-generation EGFR inhibitor for EGFR mutant non-small cell lung cancer; IND on track for submission in Q4 2023 -- -- Theseus announces ...
CAMBRIDGE, Mass., April 26, 2023 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (THRX) (Theseus or the Company), a clinical-stage biopharmaceutical company focused on improving the lives of cancer ...
-- Dose-dependent reductions observed in ctDNA KIT-mutant allele fractions for both major classes of KIT resistance mutations at exposures consistent with preclinical predictions observed in ...
Theseus Pharmaceuticals Inc (NASDAQ:THRX) on Friday, has entered into a definitive merger agreement whereby Concentra Biosciences LLC will acquire Theseus for a price per share of between $3.90 and $4 ...
-- Theseus Stockholders to Receive $4.05 Per Share in Cash Plus Contingent Value Right -- The tender offer and related withdrawal rights expired at 6:00 p.m. Eastern Time on February 13, 2024 (the ...
Byrd (Leonardo: Beautiful Dreamer) here retells an action-packed tale of the Greek hero Theseus: Theseus' childhood meeting with the strongman Heracles, his reunion with his father, King Aegeus, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results